PRESENTATION

Q4 2023 — Results presentation

Q4 2023PDF · 33 pages5.0 MB


-- 1 of 33 --



-- 2 of 33 --



-- 3 of 33 --



-- 4 of 33 --



-- 5 of 33 --



-- 6 of 33 --



-- 7 of 33 --



-- 8 of 33 --



-- 9 of 33 --

POTENTIAL APPROVALS US/EU 	PLANNED SUBMISSIONS US/EU 	POTENTIAL CLINICAL DATA
Sum of Program Change	Sum of Region Change	Sum of Check Change 	Sum of Program Change	Sum of Region Change	Sum of Check Change 	Sum of Program Change	Sum of Region Change	Sum of Check Change	Phase III
OPSUMIT (macitentan) 	US OPSUMIT (macitentan) 	US SIMPONI (golimumab) 	TREMFYA (guselkumab)
EU Pediatric Pulmonary Arterial Hypertension
(TOMORROW)
Pediatric Pulmonary Arterial Hypertension
(TOMORROW)
EU Pediatric Ulcerative Colitis 	Crohn's Disease (GALAXI)
US OPSYNVI (macitentan/tadalafil STCT) 	UPTRAVI (selexipag) 	STELARA (ustekinumab) 	TREMFYA (guselkumab)
EU Pulmonary Arterial Hypertension 	EU Pediatric Pulmonary Arterial Hypertension
(SALTO)
EU Pediatric Crohn's Disease 	Ulcerative Colitis Monotherapy (QUASAR)
US EDURANT (rilpivirine) 	US nipocalimab 	US TREMFYA (guselkumab) 	RYBREVANT (amivantamab)
EU HIV pediatric 2-12 year old 	EU Generalized Myasthenia Gravis 	Pediatric Psoriasis 	Subcutaneous (PALOMA-3)
P US^ BALVERSA (erdafitinib) 	US RYBREVANT (amivantamab) 	US TREMFYA (guselkumab) 	ERLEADA (apalutamide)
EU Urothelial Cancer (THOR) 	EU Subcutaneous (PALOMA-3) 	EU Crohn's Disease (GALAXI) 	High Risk Prostate Cancer (PROTEUS)
US DARZALEX (daratumumab) 	US DARZALEX (daratumumab) 	US TREMFYA (guselkumab) 	seltorexant
Frontline multiple myeloma transplant
eligible (PERSEUS)
EU Frontline multiple myeloma transplant
eligible (PERSEUS)
Pediatric Juvenile Psoriatic Arthritis 	Adjunctive treatment for major depressive
disorder with insomnia symptoms
US CARVYKTI (ciltacabtagene autoleucel) 	CABENUVA 	US TREMFYA (guselkumab) 	nipocalimab
EU Relapsed Refractory multiple myeloma w/1-3
PL (CARTITUDE-4)
EU HIV Adolescents 	EU Ulcerative Colitis Monotherapy (QUASAR) 	Generalized Myasthenia Gravis
US RYBREVANT (amivantamab) 	US TREMFYA (guselkumab) 	TREMFYA (guselkumab)
EU Frontline Non Small Cell Lung Cancer in
combination with chemotherapy (PAPILLON)
Ulcerative Colitis Subcutaneous Induction
(ASTRO)
Crohn's Disease Subcutaneous Induction
(GRAVITI)
US RYBREVANT / lazertinib 	US TREMFYA (guselkumab) 	aticaprant
EU Non Small Cell Lung Cancer 2L (MARIPOSA-2) 	EU Crohn's Disease Subcutaneous Induction
(GRAVITI)
Adjunctive Major Depressive Disorder
US RYBREVANT / lazertinib 	Phase II
EU Non Small Cell Lung Cancer (MARIPOSA) 	Combination Therapy
Psoriatic Arthritis
nipocalimab
Sjogren's Disease
TAR-200 (RIS/gemcitabine plus cetrelimab)
Non Muscle Invasive Bladder Cancer
Johnson & Johnson Innovative Medicine Pipeline
Key Events in 2024*
*This information is as of January 23, 2024 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. ^ BALVERSA US Full Approval

-- 10 of 33 --



-- 11 of 33 --



-- 12 of 33 --



-- 13 of 33 --



-- 14 of 33 --



-- 15 of 33 --



-- 16 of 33 --



-- 17 of 33 --

■ ■
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

-- 18 of 33 --

•
•
•
•
•
•
•
•
•
•
•
•
•
•
■ ■

-- 19 of 33 --



-- 20 of 33 --



-- 21 of 33 --



-- 22 of 33 --



-- 23 of 33 --



-- 24 of 33 --

•
➢
➢
•
➢
➢
➢

-- 25 of 33 --



-- 26 of 33 --



-- 27 of 33 --

•
–
–
–
–
–
–
•
–
–
–
–
–
•
–
•
–
–
•
–
–
–
–
–
–
–

-- 28 of 33 --

■ ■
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

-- 29 of 33 --

•
•
•
•
•
•
•
•
•
•
•
•
•
•
■ ■

-- 30 of 33 --



-- 31 of 33 --



-- 32 of 33 --

POTENTIAL APPROVALS US/EU 	PLANNED SUBMISSIONS US/EU 	POTENTIAL CLINICAL DATA
Sum of Program Change	Sum of Region Change	Sum of Check Change 	Sum of Program Change	Sum of Region Change	Sum of Check Change	Phase III 	Phase I/II
P US AKEEGA (niraparib/abiraterone) 	P US AKEEGA (niraparib/abiraterone) 	P CARVYKTI (ciltacabtagene autoleucel) 	P TAR-200 (RIS/gemcitabine plus cetrelimab)
P EU L1 Prostate cancer metastatic castration-
resistant (MAGNITUDE)
L1 Prostate cancer metastatic castration-
resistant (MAGNITUDE)
Relapsed Refractory multiple myeloma w/1-3
PL (CARTITUDE-4)
Non muscle invasive bladder cancer (SR-1 Early
Data)
P US TALVEY (talquetamab) 	TALVEY (talquetamab) 	P BALVERSA (erdafitinib) 	P TAR-210 (RIS/erdafitinib)
P EU Relapsed Refractory Multiple Myeloma 	P EU Relapsed Refractory Multiple Myeloma 	Urothelial Cancer (THOR) 	Non Muscle Invasive Bladder Cancer (Early
Data)
P US ERLEADA (apalutamide) 	P US BALVERSA (erdafitinib) 	P RYBREVANT (amivantamab) 	P TAR-200 (RIS/gemcitabine plus cetrelimab)
P EU Tablet Reduction 	P EU Urothelial Cancer (THOR) 	Frontline Non Small Cell Lung Cancer in
combination with chemotherapy (PAPILLON)
Non Muscle Invasive Bladder Cancer (SunRISe-1
Update)
TECVAYLI (teclistamab) 	P US CARVYKTI (ciltacabtagene autoleucel) 	P IMBRUVICA (ibrutinib) 	P BALVERSA (erdafitinib)
P EU Relapsed Refractory Multiple Myeloma
Biweekly Dosing
P EU Relapsed Refractory multiple myeloma w/1-3
PL (CARTITUDE-4)
Relapsed Refractory patients with Mantle Cell
Lymphoma in combination with venetoclax
(SYMPATICO)
Tumor Agnostic (RAGNAR)
P US EDURANT (rilpivirine) 	P RYBREVANT / lazertinib 	RYBREVANT (amivantamab)
P EU HIV pediatric 2-12 year old 	Non Small Cell Lung Cancer 2L (MARIPOSA-2) 	Solid Tumors (GIC2001)
OPSUMIT (macitentan) 	P RYBREVANT / lazertinib 	P JNJ-2113
P EU Pediatric pulmonary arterial hypertension
(TOMORROW)
Non Small Cell Lung Cancer (MARIPOSA) 	Psoriasis
P US OPSYNVI (macitentan/tadalafil STCT) 	P OPSYNVI (macitentan/tadalafil STCT) 	P nipocalimab
P EU Pulmonary arterial hypertension 	Pulmonary arterial hypertension (A DUE) 	Rheumatoid Arthritis
P US RYBREVANT (amivantamab) 	P SPRAVATO (esketamine) 	P nipocalimab
P EU Frontline Non Small Cell Lung Cancer in
combination with chemotherapy (PAPILLON)
Treatment Resistant Major Depressive
Disorder (ESCAPE-TRD)
Hemolytic disease of the fetus and newborn
P US RYBREVANT / lazertinib 	TREMFYA (guselkumab) 	P JNJ-5322 (BCMA/BPRC5D/CD3)
P EU Non Small Cell Lung Cancer 2L (MARIPOSA-2) 	Crohn's Disease (GALAXI) 	Hematological Malignancies (Ph I Data)
P US RYBREVANT / lazertinib 	P TREMFYA (guselkumab)
P EU Non Small Cell Lung Cancer (MARIPOSA) 	Ulcerative Colitis Monotherapy
P DARZALEX (daratumumab)
Frontline multiple myeloma transplant
eligible (PERSEUS)
Johnson & Johnson Innovative Medicine Pipeline
Key Events in 2023*
*This information is as of January 23, 2024 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

-- 33 of 33 --